Biotech M&A Targets Focus on Late-Stage GLP-1, Oncology and CNS Assets

The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs, with pharmaceutical companies increasingly prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. This strategic shift places companies with advanced clinical programs in metabolic disorders, oncology, and central nervous system indications into focus as acquisition targets aligned with current M&A priorities.

Viking Therapeutics is the most direct GLP-1 acquisition target in the sector. Its lead asset, VK2735, is a dual GLP-1/GIP receptor agonist in both subcutaneous and oral formulations. The VANQUISH Phase 3 program has enrolled more than 4,500 patients, with VANQUISH-2 completing enrollment in Q1 2026. Oral VK2735 demonstrated up to 12.2% body weight reduction at 13 weeks in Phase 2, with Phase 3 set to begin Q3 2026. A Polymarket prediction market currently prices a Viking acquisition before 2027 at roughly 25.5% implied probability.

Structure Therapeutics is building what could be the best-in-class oral GLP-1 franchise. Its lead asset, aleniglipron, delivered placebo-adjusted mean weight loss of 11.3% at 120 mg and 15.3% at 240 mg at 36 weeks in the Phase 2b ACCESS trial, with no plateau observed. Higher-dose 44-week ACCESS II data are expected Q1 2026, and a Phase 3 registrational program is planned for H2 2026. The oral amylin pipeline adds differentiation, with ACCG-2671 in Phase 1 and ACCG-3535 demonstrating superior weight loss versus semaglutide monotherapy in combination studies.

Revolution Medicines is the oncology diversification play for a metabolic-focused acquirer. While not a GLP-1 company, its RAS(ON) inhibitor platform targeting PDAC and NSCLC is among the most advanced precision oncology pipelines in biotech. A Phase 3 readout for daraxonrasib in second-line metastatic PDAC is expected H1 2026, and zoldonrasib holds FDA Breakthrough Therapy designation in NSCLC with RAS G12D mutations. A combination study showed a 63% partial response rate and 95% disease control rate in 19 evaluable PDAC patients.

Vera Therapeutics offers a near-term commercial catalyst in autoimmune kidney disease. Atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, achieved a 46% reduction in proteinuria at week 36 in the Phase 3 ORIGIN 3 trial, with data published in the New England Journal of Medicine. The BLA has been granted priority review with a PDUFA date of July 7, 2026, and the company is commercially prepared for a mid-2026 U.S. launch.

Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success.

Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets.

This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry.